ACCESS Newswire
24 Jan 2023, 16:35 GMT+10
ORLANDO, FL / ACCESSWIRE / January 24, 2023 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a pioneer in the science of using novel transdermal solutions and other innovative technologies, today announced details of the Company's participation at the 2023 Transdermal and Microneedle Conference taking place January 23-24, 2023, at the Copthorne Tara Hotel, London, United Kingdom.
Gareth Sheridan, Nutriband's CEO, will give a presentation at 11:00 a.m. GMT on January 24th entitled ‘Improving existing transdermal technologies to reduce the liability profile of abusable medications' which will provide an overview of the development of transdermal drug delivery systems using Nutriband's AVERSA technology as a reference point.
Nutriband COO and President of its 4P Therapeutics subsidiary, Dr. Alan Smith, will participate in a panel discussion at 11:40 a.m. GMT on January 24th on the topic of microneedles as a therapeutic tool. The panel will be moderated by James Birchall, Professor of Pharmaceutical Sciences, Cardiff University.
An overview of the panel discussion is as follows:
Reviewing microneedles technologies as a novel therapeutic tool for drug delivery
Conference presentations and panelists are also expected from Merck (NYSE: MRK), GSK (NYSE: GSK), Sanofi (NASDAQ: SNY), Rani Therapeutics (NASDAQ: RANI), Leo Pharmaceuticals, Vaxxas and Starton Therapeutics.
About AVERSA™ Technology
AVERSA™ abuse deterrent transdermal technology incorporates aversive agents to prevent the Abuse, DiVERsion, MiSuse and Accidental exposure of drugs with abuse potential specifically Opioids. Our first application for AVERSA is for our abuse deterrent fentanyl transdermal patch which we are developing to provide clinicians and patients with an extended release chronic pain relief. The goal is to make these pain treatments safe for all who need them. When used correctly they provide incredible relief and care to chronic pain patients.
About Nutriband Inc.
We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse deterrent fentanyl patch incorporating our AVERSA™ abuse deterrence technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
The Company's website is www.nutriband.com. Any material contained in or derived from the Company's websites or any other website is not part of this press release.
Forward-Looking Statements
This communication contains 'forward-looking statements.' Such statements may be preceded by the words 'intends,' 'may,' 'will,' 'plans,' 'expects,' 'anticipates,' 'projects,' 'predicts,' 'estimates,' 'aims,' 'believes,' 'hopes,' 'potential,' or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified, and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) difficulties in obtaining financing on commercially reasonable terms; (ii) changes in the size and nature of our competition; (iii) loss of one or more key executives or brand ambassadors; and (iv) changes in legal or regulatory requirements in the markets in which we operate. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
For more information, contact:
Investor Relations
RedChip Companies
Dave Gentry
[email protected]
1-800-RED-CHIP (733-2447)
407-491-4498
SOURCE: Nutriband Inc.
Get a daily dose of Miami Mirror news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Miami Mirror.
More InformationLONDON, U.K.: This week, BP appointed Simon Henry, former Shell finance chief, to its board as a non-executive director effective September...
OTTAWA, Canada: With Canada Post struggling to maintain operations amid labour unrest, rivals like FedEx and UPS are stepping in to...
NEW YORK, New York - U.S. and global markets showed a mixed performance in Tuesday's trading session, with some indices edging higher...
PARIS, France: French military and intelligence officials have accused China of orchestrating a covert campaign to damage the reputation...
NEW DELHI, India: Birkenstock is stepping up its efforts to protect its iconic sandals in India, as local legal representatives conducted...
HONG KONG: China has fired back at the European Union in an escalating trade dispute by imposing new restrictions on medical device...
MOSCOW, Russia: Just hours after his sudden dismissal by President Vladimir Putin, Russia's former transport minister, Roman Starovoit,...
DHARAMSHALA, India: The Dalai Lama turned 90 on July 6, celebrated by thousands of followers in the Himalayan town of Dharamshala,...
ZAGREB, Croatia: A massive concert by popular Croatian singer Marko Perković, known by his stage name Thompson, has drawn widespread...
WASHINGTON, D.C.: Elon Musk's entry into the political arena is drawing pushback from top U.S. officials and investors, as his decision...
CULVER CITY, California: TikTok is preparing to roll out a separate version of its app for U.S. users, as efforts to secure a sale...
WASHINGTON, D.C.: President Donald Trump claimed he was unaware that the term shylock is regarded as antisemitic when he used it in...